CAMPBELL, CA–(Marketwired – Apr 14, 2016) – Friendable, Inc. (OTC PINK: FDBL), a mobile application developer, is pleased to announce that its submission of a major app update for Friendable iOS/iPhone users has been approved and is now available in the Apple iTunes App Store. These major app updates completed in the iOS version of the Friendable app were designed to spur new user downloads and registrations.
Among the upgrades included are the following features:
Users can now sign in and connect using Facebook, the world’s largest social network.
A new proprietary location database connected to Google Places.
An all-new registration and onboarding process, making the signup process faster and simpler.
Event selectors are now icon based, adding ease and charm to each action.
Updated User Interface (UI) to the all-important member profile screens.
“Our entire team is in agreement, these updates significantly improve the user experience for iOS users making the Friendable app even friendlier,” said Robert Rositano, Jr., CEO, Friendable, Inc. “The updated integration with Facebook is a big deal for us, among various other advancements and by using a trusted verification platform like Facebook to incent users to login using this method, is just one more feature that will improve the user experience. We expect these changes to significantly increase new user signups and provide the foundation to boost revenue opportunities as we continue our focus on overall user population and growth.”
About Friendable: Friendable Inc. is a mobile application developer whose Friendable app makes it simple and easy for users to make connections and meet new friends using shared interests and location. These interactions allow Friendable to generate ad revenue by providing advertisers such as restaurants, bars and events with the opportunity to reach potential customers when it matters most: which is when Friendable users are nearby and searching for something to do.
Cautionary Language Concerning Forward-Looking Statements This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected by Friendable, Inc. The iTunes rankings should not be construed as an indication in any way whatsoever of the future value of the Friendable’s common stock or its present or future financial condition. The public filings of Friendable, Inc. made with the Securities and Exchange Commission may be accessed at the SEC’s Edgar system atwww.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Friendable, Inc. cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, Friendable, Inc. does not undertake, and Friendable, Inc. specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. EmergingGrowth.com may either hold a stock position in or have been compensated by or for a company or companies discussed in this article. EmergingGrowth.com does not have a stock position in any securities discussed in this article. Please view our full disclosure which can be found here,https://www.emerginggrowth.com/disclosure-3325/. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.
Johnson & Johnson (NY:JNJ) applied for an emergency use authorization from the Food and Drug Administration for its coronavirus vaccine after releasing data last week showing it was about 66% effective in protecting against the virus.
An experimental coronavirus vaccine taken by mouth showed promising results in an early-stage clinical trial of 35 healthy adults, South San Francisco-based Vaxart (NQ: VXRT) said Wednesday. Despite the results, Vaxart’s (NQ: VXRT) stock plunged 60% in intraday trading.
Across all geographies, the vaccine was 85% effective in preventing severe cases of Covid-19 after four weeks, according to J&J (NYSE: JNJ). Protection improved over time, the company said, with zero participants reporting a severe case after 49 days. Additionally, J&J (NYSE: JNJ) said the vaccine provided complete protection against Covid-related hospitalizations after four weeks.
Avalon GloboCare is in the process of establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bio architectures and Professor Uwe Sleytr, a member of the Austrian Academy of Sciences.
Short-sellers have lost about $20 billion this month, including a nearly $8 billion loss on Friday as the stock jumped 68%, according to data from S3 Partners. Following GameStop, retail investors dove into other heavily-shorted stocks like BlackBerry (NY:BB), AMC Entertainment (NY:AMC) and Bed Bath & Beyond (NQ BBBY).
Avalon GloboCare is in the process of establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bio architectures and Professor Uwe Sleytr, a member of the Austrian Academy of Sciences. In connection with the new facility, Avalon and BOKU have signed a Memorandum of Understanding (MOU) to jointly apply for a matching research grant from the prestigious Christian Doppler Laboratory Foundation. Avalon also has research being done in MIT (Massachusetts Institute of Technology), the UNRLS (University of Natural Resources and life sciences in Australia), Weill Cornell Medicine in New York City and the Lu Daopei Medical Group in China, which has the country’s top ranked hematology and bone marrow transplant program
When it comes to Covid-19 vaccines, experts and public health officials say it’s crucial to combat misinformation (false or inaccurate information) and the more nefarious disinformation (false information intended to mislead people) being spread about inoculations. Here are some of the main myths that are circulating about coronavirus vaccines.
Rapid COVID-19 testing could be a game-changer in the weeks and months ahead. Vaccine rollout in the U.S. has been slow. The fight to control the spread of the virus is expected to intensify as new infectious variants of the disease pop up in the U.S.
Pfizer (NYSE: PFE) will supply up to 40 million doses of its coronavirus vaccine to a global alliance aiming to provide poor nations with coronavirus vaccines, the head of the World Health Organization said Friday.The deal will allow Covax — co-led by the WHO — to begin delivering vaccine doses to participating countries in February, WHO’s Director-General Tedros Adhanom Ghebreyesus said during a press briefing.
While children are less affected by Covid-19 than adults, they do still catch the virus and get sick. Some have even died. More than 2.5 million cases of Covid-19 had been reported in children as of Jan. 14, about 13% of all cases, according to a report from the American Academy of Pediatrics and the Children’s Hospital Association.